Osborne Clarke in Amsterdam advises iOnctura on extension Series A financing to €20.1M

Written on 15 July 2020

Osborne Clarke in Amsterdam has advised iOnctura, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, in raising an additional EUR 5.1 million bringing the total Series A financing to EUR 20.1 million.

New investors 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR joins the existing blue chip investor syndicate of M Ventures, INKEF Capital, VI Partners, and Schroder Adveq, which all participated in the extension.

The Osborne Clarke in Amsterdam team consisted of Partner Herke van Hulst, Senior Associate Geoffrey Beurskens and Associate Florien Sanders (Corporate M&A), and Partners Cars-Jan van Gool (Civil Law Notary) and Associate Arlette Vrolijk (Candidate Civil-Law Notary).

Osborne Clarke’s international life science and healthcare sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market. Recent notable work from the team in Amsterdam includes advising the syndicate of investors in the EUR 32 million Series B financing round of VarmX.

Connect with one of our experts

Herke van Hulst

Partner, Advocaat, The Netherlands

T +31 20 702 8672

Email Herke

Full Biog

Geoffrey Beurskens

Senior Associate, Advocaat, The Netherlands

T +31 20 702 8682

Email Geoffrey

Full Biog

Florien Sanders

Associate, Advocaat, The Netherlands

M +31 6 2943 2775

Email Florien

Full Biog

Cars-Jan van Gool

Partner, Civil Law Notary (notaris), The Netherlands

T +31 20 702 8664

Email Cars-Jan

Full Biog

Arlette Vrolijk

Associate, Civil Law Notary (kandidaat-notaris), The Netherlands

T +31 20 70 28 630

Email Arlette

Full Biog